Adenosine 5′-Triphosphate Test in the Management of Patients With Syncope
Authors:
- 1 November 2016
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 23 (6) , e1347-e1352
Abstract
The response to adenosine 5′-triphosphate (ATP) identifies patients with syncope who might benefit from pacemaker therapy (ATP test). Two measures have been used to determine the outcome of the ATP test, which have lead to contrasting conclusions regarding its utility: (1) the duration of cardiac pause (CP) mainly due to AV block and (2) the longest RR interval (RRmax). We tested the hypothesis that the discrepancy regarding the utility of the ATP test is mainly because of the different way the 2 measures determine the outcome of the test. Post hoc analysis was applied to data obtained from patients with syncope (n = 33) with a positive and negative ATP test based on the CP duration and RRmax, respectively, subjected to pacemaker therapy. In 19 and 14 patients, the pacemaker was programmed to function as AAI pacing at 30 ppm (control) and as DDD pacing at 70 ppm, respectively. During the follow-up period of 17.0 ± 8.6 months, syncope recurred in only 1 of the 14 patients with DDD pacing; in contrast, 10 of 19 patients with AAI30 pacing experienced syncope within the first 5.3 ± 5.2 months of follow-up (P< 0.009; recurrence rate). The ATP test, the outcome of which is determined by the CP measure, is a useful diagnostic test for the identification of patients with bradycardic syncope who may benefit from pacemaker therapy; the identification of such patients would be missed when the RRmaxmeasure is used to determine the outcome of the test. The efficacy of DDD pacing suggests that atrioventricular nodal conduction block is the primary cause of syncope in patients with a positive ATP test based on the CP measure.Keywords
This publication has 26 references indexed in Scilit:
- The Mechanism of the Negative Chronotropic and Dromotropic Actions of Adenosine 5'-triphosphate in the Heart: An UpdateJournal of Cardiovascular Pharmacology, 2010
- The birth and postnatal development of purinergic signallingActa Physiologica, 2010
- Basal Release of ATP: An Autocrine-Paracrine Mechanism for Cell RegulationScience Signaling, 2010
- Purine and pyrimidine receptorsCellular and Molecular Life Sciences, 2007
- Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndromeEuropean Heart Journal, 2005
- Sinus slowing caused by adenosine-5′-triphosphate in patients with and without sick sinus syndrome under various autonomic statesJournal of Electrocardiology, 2004
- Adenosine 5′-Triphosphate: a P2-Purinergic Agonist in the MyocardiumPhysiological Reviews, 2001
- Extracellular metabolism of ATP and other nucleotidesNaunyn-Schmiedeberg's Archives of Pharmacology, 2000
- Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart: Clinical and experimental aspectsJACC, 1984
- Value of purinic compounds in assessing sinus node dysfunction in man: A new diagnostic methodEuropean Heart Journal, 1984